Eric Lefkofsky is revolutionizing the way we approach cancer treatment. His latest venture, Tempus, will utilize big data to battle cancer in a way that we have never seen before. Tempus is a technology operating system that will collect and harvest data from cancer patients. The data will then be available to physicians everywhere. While the technology is extremely complicated for us laymen, the possibilities are absolutely endless.
Eric Lefkofsky has previously launched multiple successful startups throughout a variety of technology verticals. He is the founding partner of an investment company called Lightbank. The company specializes in investing in technologies with the potential to disrupt the market place in a major way. He also founded Groupon.
Eric and his wife founded the Lefkofsky Family Foundation in 2006 to support their commitment to philanthropy in their own community and beyond. The private charitable foundation focuses on initiatives with the potential to make major impacts in the world of education, arts, human rights and technology. Lefkofsky also is an adjunct professor at the University of Chicago and is a Trustee of The Art Institute of Chicago and the Lurie Children’s Hospital of Chicago.
Huge News for Tempus
According to Eric Lefkofsky’s prediction, more than 25% of cancer patients will be touched by Tempus in some way in 2018. That number is certainly bound to grow after the announcement that Tempus has gained access to CancerLinQ through a partnership with artificial intelligence company Precision Health AI.
This 10-year partnership will give Tempus access to data from more than 600,000 cancer patients. This data will go a long way in building the world’s first and largest library of data from cancer patients. Tempus wants to build a full operating system that houses this data and makes it available to oncologists across the world
Tempus has already foraged partnership with over fifty major medical research hospitals in the United States. Among these are some of the largest research facilities in the country, including the Mayo Clinic, the Cleveland Clinic and Northwestern.
Access to CancerLinQ puts Tempus one step closer to their goal of battling cancer through big data.